Evidence map›Paper›PMID 40118155›Full record

ArticleOphthalmology2026

Safety Assessment of Aqueous Humor Liquid Biopsy in Retinoblastoma: A Multicenter Study of 1203 Procedures.

Douglas Chigane, Drishti Pandya, Muskaan Singh, Brianne Brown, Michelle Lin, Liya Xu, Andrew W Stacey, Alyssa C Bonnell, G Baker Hubbard, Hans Grossniklaus and 13 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Update on Retinoblastoma Therapies.Medicina (Kaunas, Lithuania) · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Douglas ChiganeDivision of Ophthalmology, Children's Hospital Los Angeles, Los Angeles, California.
Drishti PandyaDivision of Ophthalmology, Children's Hospital Los Angeles, Los Angeles, California.
Muskaan SinghUSC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.
Brianne BrownDivision of Ophthalmology, Children's Hospital Los Angeles, Los Angeles, California.
Michelle LinDivision of Ophthalmology, Children's Hospital Los Angeles, Los Angeles, California.
Liya XuDivision of Ophthalmology, Children's Hospital Los Angeles, Los Angeles, California; USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California; The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California.
Andrew W StaceyDivision of Ophthalmology, Department of Ophthalmology, Seattle Children's Hospital, University of Washington, Seattle, Washington.
Alyssa C BonnellDivision of Ophthalmology, Department of Ophthalmology, Seattle Children's Hospital, University of Washington, Seattle, Washington.
G Baker HubbardEmory Eye Center, Emory University School of Medicine, Atlanta, Georgia.
Hans GrossniklausEmory Eye Center, Emory University School of Medicine, Atlanta, Georgia.
Alison H SkaletDepartment of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Kellyn N BellsmithDepartment of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Sara E LallyOcular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Margarida Simão-RafaelSant Joan de Déu Barcelona Hospital, Esplugues de Llobregat, Barcelona, Spain.
Cristina Jou MuñozSant Joan de Déu Barcelona Hospital, Esplugues de Llobregat, Barcelona, Spain.
Jaume Català-MoraSant Joan de Déu Barcelona Hospital, Esplugues de Llobregat, Barcelona, Spain.
Denis MalaiseDepartment of Ocular Oncology, Institut Curie, Paris, France.
Livia Lumbroso-Le RouicDepartment of Ocular Oncology, Institut Curie, Paris, France.
Alexandre MatetDepartment of Ocular Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France.
Guillermo L ChantadaSant Joan de Déu Barcelona Hospital, Esplugues de Llobregat, Barcelona, Spain.
Nathalie CassouxDepartment of Ocular Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France.
Carol L ShieldsOcular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Jesse L BerryDivision of Ophthalmology, Children's Hospital Los Angeles, Los Angeles, California; USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California; The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California. Electronic address: jberry@chla.usc.edu.

Funding

Validation of an aqueous humor liquid biopsy for molecular prognostication and monitoring of children with retinoblastoma.R01CA282759 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI Jesse L Berry · 2023 to 2026
$2.2M
Development of a surrogate liquid biopsy from the aqueous humor in retinoblastoma eyes.K08CA232344 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI BERRY, JESSE L · 2018 to 2022
$1.1M
NCI NIH HHS K08 CA232344NCI NIH HHS R01 CA282759
6 · The paper itself

Abstract

purposeTo evaluate the safety profile of aqueous humor (AH) liquid biopsy in pediatric patients with retinoblastoma and retinoblastoma-simulating lesions through a multicenter analysis of paracentesis procedures.

designRetrospective multicenter study.

participantsA total of 1203 paracentesis procedures were performed on 484 eyes of 425 pediatric patients, including 352 patients with retinoblastoma and 73 patients with retinoblastoma-simulating lesions.

methodsMedical records were reviewed retrospectively to identify complications from anterior chamber paracentesis performed to obtain AH for liquid biopsy. Procedures were conducted during routine examination under anesthesia. Aqueous humor samples were extracted using a 32-gauge needle and underwent cell-free DNA analysis. Complications were classified as mild, moderate, or severe based on clinical impact and required interventions.

main outcome measuresIncidence and severity of complications related to the paracentesis procedure.

resultsAmong 1203 procedures, 1 mild complication was identified, representing an overall complication rate of 0.08%. No moderate or severe complications, including vision, eye loss, extraocular tumor spread, or death, were observed at a median follow-up of 16 months. The procedure demonstrated an excellent safety profile across multiple centers, with no permanent adverse outcomes.

conclusionsAqueous humor liquid biopsy via anterior chamber paracentesis is a safe and well-tolerated procedure in pediatric patients with retinoblastoma when performed by trained ocular surgeons under general anesthesia. This large-scale analysis supports the procedure's use as a minimally invasive diagnostic tool with minimal risk, providing valuable molecular insights for retinoblastoma management. These findings offer reassurance to clinicians and parents regarding the safety of AH liquid biopsy for retinoblastoma. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Aqueous HumorParacentesisRetinal NeoplasmsRetinoblastomaAnterior ChamberCell-Free Nucleic AcidsChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantLiquid BiopsyMaleRetrospective StudiesCell-Free Nucleic AcidsAqueous humorLiquid biopsyRetinoblastomaSafety

Identifiers

PMID40118155
PMCPMC12519347

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.